Get started
Author

M. Martín Jiménez

Observed names: M Martin Jimenez, M Martín Jiménez, M. Martin Jimenez, MIGUEL MARTÍN JIMÉNEZ, Miguel Jiménez, Miguel Martin Jimenez, Miguel Martin Jiménez, Miguel Martín Jimenez, Miguel Martín Jiménez
Observed institutions: Universidad Complutense de Madrid, University of Alberta, Instituto de Salud Carlos III, Hospital General Universitario Gregorio Marañón, Hospital Clínico San Carlos, Klinička bolnica "Sveti Duh", Complejo Hospitalario de Navarra, Regional Hospital Randers, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, Sociedad Española de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad de Navarra
OpenAlex ID: A5114068377
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 479
PDF
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
2021 · Lori J. Goldstein, Mauro Mansutti, et al. · Breast Cancer Research and Treatment · 94
PDF
211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
2022 · M. Martin Jimenez, E. Lim, et al. · Annals of Oncology · 54
PDF
LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial
2024 · P.A. Fasching, D. Stroyakovskiy, et al. · Annals of Oncology · 50
PDF
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model
2014 · A. J. Muñoz Martín, P. García Alfonso, et al. · Clinical & Translational Oncology · 50
Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors
1998 · Pedro León, Miguel Jiménez, et al. · Medical and Pediatric Oncology · 41
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
2022 · E.P. Hamilton, C.L. Shapiro, et al. · Annals of Oncology · 35
Clinical guide SEOM on venous thromboembolism in cancer patients
2014 · A. J. Muñoz Martín, C. Font Puig, et al. · Clinical & Translational Oncology · 29
PDF
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
2023 · N. Harbeck, P. Rastogi, et al. · Annals of Oncology · 21
PDF
Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status
2020 · L. Ortega Morán, P. García Alfonso, et al. · Clinical & Translational Oncology · 16
Outpatient management of incidental pulmonary embolism in cancer patient
2019 · Andrés J. Muñoz Martín, Magdalena Carmen Ruiz Zamorano, et al. · Clinical & Translational Oncology · 14
Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies
2006 · Javier Puente Vázquez, Sara López-Tarruella Cobo, et al. · Clinical & Translational Oncology · 13
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma
2025 · Joel Randolph Hecht, Arjun Oberoi, et al. · The Oncologist · 11
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
2022 · J. Furlanetto, F. Marmé, et al. · Annals of Oncology · 11
PDF
Overview of virus and cancer relationships. Position paper
2021 · Emilio Bouza, Miguel Martín Jiménez, et al. · Revista Española de Quimioterapia · 11
PDF
Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors
2021 · Giuseppe Curigliano, Miguel Martin Jimenez, et al. · Cancer Research · 11
Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2
2016 · ANDRÉS J. MUÑOZ MARTÍN, PILAR GARCÍA ALFONSO, et al. · Oncology Letters · 10
PDF
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
2022 · P. Neven, P.A. Fasching, et al. · Annals of Oncology · 8
273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
2023 · P. Neven, N. Stahl, et al. · Annals of Oncology · 7
PDF
7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer
2023 · E. Sanfeliu Torres, G. Villacampa, et al. · ESMO Open · 7
PDF
Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
2017 · M. Martin Jimenez, F.A. Holmes, et al. · Annals of Oncology · 7
113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)
2024 · C.H. Barrios, N. Harbeck, et al. · ESMO Open · 6
PDF
Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study
2017 · M. Ruiz-Borrego, M. Martin Jimenez, et al. · Annals of Oncology · 6
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
2009 · Alfredo Carrato Mena, Luis Paz-Ares Rodríguez, et al. · Clinical & Translational Oncology · 5
EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)
2017 · M. Martin Jimenez, T. Bachelot, et al. · Annals of Oncology · 4
Works count: 93
Citation count: 1,064
H-index: 12
I10-index: 17
Year
Topic
Type